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Abstract: Multiple sclerosis (MS) is a chronic demyelinating neurological disorder affecting 
people worldwide; women are affected more than men. MS results in serious neurological deficits 
along with behavioral compromise, the mechanisms of which still remain unclear. Behavioral 
disturbances such as depression, anxiety, cognitive impairment, psychosis, euphoria, sleep 
disturbances, and fatigue affect the quality of life in MS patients. Among these, depression and 
psychosis are more common than any other neurological disorders. In addition, depression is 
associated with other comorbidities. Although anxiety is often misdiagnosed in MS patients, 
it can induce suicidal ideation if it coexists with depression. An interrelation between sleep 
abnormalities and fatigue is also reported among MS patients. In addition, therapeutics for MS 
is always a challenge because of the presence of the blood–brain barrier, adding to the lack of 
detailed understanding of the disease pathology. In this review, we tried to summarize various 
behavioral pathologies and their association with MS, followed by its conventional treatment 
and nanotheranostics.
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Introduction
Multiple sclerosis (MS) is a chronic neurological autoimmune disease characterized 
by erosions of myelin, the protective nerve sheath, with a partial preservation or 
complete loss of axonal activity and nerve transmission.1 However, remyelination is 
often possible once inflammation subsides and is mediated by oligodendrocytes, which 
secrete myelin. Remyelination process can be explained as the phenomenon of newer 
myelin sheath formation around the damaged axons. It is better explained as more 
the number of oligodendrocytes around the affected neurons, the faster the process 
of remyeliantion. Inadequate number of oligodendrocytes may lead to improper or 
no myelin formation, resulting in abnormal neuronal functioning.2 MS has affected 
more than 1 million people worldwide. The symptoms of MS are weakness, loss of 
senses, shuffling gait, loss of vision, and cognition.3,4 The main driving force involved 
in the pathology of MS is inflammation, which enhances autoreactivity, followed by 
demyelination and neuronal damage.5 Histopathological studies have also confirmed 
multicentered inflammatory lesions, which spread throughout the brain and spinal 
cord.6 Autoreactive T-cells are the key players involved in disease generation, breaking 
down the margin of autoreactivity and self-tolerance, and multiple etiological factors 
are responsible for this activation. The existence of autoreactive T-cells is evident in 
both normal and MS patients, but they turn active and seem to be devastating only in 
MS.7 Among all the T-cell clones, CD8 subtype is found to be more associated with 
the disease, both in number and infiltration when assessed in the brain and spinal cord. 
CD8 T-cells were also found to be persistent in blood and cerebrospinal fluid (CSF), 
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implying the fact that they were activated consistently by an 
antigen driving the long-lasting autoimmune reactivity.8
In brief, a group of activated T-cell subclones specific 
to the myelin protein will penetrate the blood–brain barrier 
(BBB), being potentiated by the existing inflammatory cytok-
ines, while the resting T-cells have a restricted access to the 
BBB.9 The coupling of T-cell surface molecules – integrins, 
selectins, and cadherins – with the corresponding adhe-
sion molecules present in brain capillary endothelial cells 
facilitates the entry of T-cells. Once the T-cells gain entry, 
they unleash the autoimmune reactions targeting the myelin 
antigen. The activation of antibody-producing B-cells further 
enhances this autoreactivity, thus driving the degeneration 
of neurons.10 Figure 1 shows MS pathogenesis. Symptom 
severity, disability levels, and rate of disease progression vary 
with each individual and even differs in the same patient with 
time.11 Significant sex differences were identified among MS 
patients, with a majority of females displaying the symptoms 
compared to males.
Also, MS was found to affect women at an early age 
(18–30 years), while it affected men at a later stage of life 
(30–40 years). These dissimilarities were possibly due to the 
protective effects of testosterone in men. Another interesting 
aspect observed in MS was the cessation of disease symptoms 
in pregnant women who were in the third trimester. The 
elevated levels of estriol were anticipated to be responsible 
for the protective effect, and the same was observed in 
mice models as well.12 The introduction of biomarkers has 
revolutionized the understanding of the disease pathology 
and its diagnostics. Some of the recent advancements are 
the discovery of elevated levels of astrocyte and axonal 
cytoskeletal proteins, namely, glial fibrillary acidic protein 
and neurofilament light protein in the CSF corresponding to 
MS progression.13
The elevated levels of the 14-3-3 protein in the CSF cor-
responded to the disease progression and disability, while a 
close correlation was established with the downregulation of 
cystatin-C, a protease inhibitor that neutralizes the actions of 
lysosomal cathepsins modulating lymphocytic activation.14 
Some other recently found potential biomarkers associated 
with the disease are osteopontin and pentosidine.15,16 Based 
on the symptoms, MS is categorized into four subtypes. 
Patients with relapsing remitting form recover with no 
symptoms following disease onset. Patients with persistent 
disability symptoms between the cycles of relapses and 
recoveries are termed as “secondary-progressive” patients. 
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Figure 1 Pathogenesis of MS.
Notes: Lymphocytes activated due to various insults (inflammation, antigen presentation, free radicals, etc) will invade the blood–brain barrier. Initially, they bind with 
the cell adhesion molecules present on the capillary endothelium and gain access into the brain. Once inside, the reactive cells attract both the immune cell traffic (T- and 
B-cells) and mediate the devastating cascade. Cytotoxic T-cells release granzymes, and activated B-cells produce antibodies against the myelin sheath, thus mediating the 
demyelination process.
Abbreviations: MS, multiple sclerosis; Abs, antibodies.
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“Primary-progressive” MS is characterized by symptoms of 
only progression, but no signs of remission. In “progressive-
relapsing” MS, patients display severe symptoms and attacks 
during the period of remission.17
MS is not only associated with neurological symptoms 
but also with a variety of behavioral disturbances such as 
depression, anxiety, cognitive loss, psychosis, euphoria, sleep 
disturbances, and fatigue. The impact of these psychologi-
cal disturbances is such that MS at times is misdiagnosed, 
supposing it to be a behavioral disorder. In patients with 
MS, depression is the most common behavioral disorder 
followed by psychosis.18,19 The disease profession is highly 
variable with a majority of the neurological compromise fol-
lowing the relapses. In particular, RRMS is a critical subtype 
that always follows a prolonged deterioration and poses a 
serious threat of progressive disability. The symptoms of 
depression and anxiety are very common during the early 
course of the disease, though the correlation is poor toward 
the lesional load.
Cognitive impairment is often seen as a forerunner of 
MS, presenting the symptoms of hampered levels of memory, 
attention, and execution. According to magnetic resonance 
imaging (MRI) studies, the severity of cognition loss is 
relative to the cerebral white matter lesions associated with 
MS progression. Correlations also exist between the white 
matter lesions and the onset of psychosis, which is seldom 
seen in MS.20 Hence, early identification of these behavioral 
abnormalities would certainly help in diagnosing the onset 
of MS and can be invaluable for the disease management. 
Behavioral disorders and their association with MS are 
described as follows:
Depression and MS
Depression is the most common behavioral disorder prevail-
ing among MS patients. The frequency of occurrence and 
tendency to develop depressive symptoms were higher in 
patients with MS compared to patients with other chronic 
neurological disorders. However, depression often remains 
undiagnosed and untreated in MS patients. Several factors 
related to genetics, psychology, immunology, and inflamma-
tion have a role in mediating the depressive pathology in MS. 
The higher prevalence of depression in MS could possibly 
be explained as: both depression and MS are central nervous 
system disorders and share multiple etiological factors in their 
pathophysiology. Also, elevated levels of proinflammatory 
cytokines and imbalances in monoaminergic neurotrans-
mitter metabolism observed in MS were also reflected in 
depression.21 Likewise, a study reported genetic influence,22 
while a brain MRI study showed the evidence of inflammatory 
markers in the lesions and pleocytosis in the CSF.
The symptoms of depression were found to be associated 
with the lesions seen in the arcuate fasciculus23 and medial 
orbitofrontal regions. They were also associated with poor 
perfusion rate in the left cerebral hemisphere, while in the 
right cerebral hemisphere, the frontal lesion load and tem-
poral brain volume were involved.24
Similarities between MS and depression
There are some similarities between the pathologies of MS 
and depression. The lesions in arcuate fasciculus were found 
to detach few regions of the cerebral cortex. The lesions were 
evident in the frontotemporal region, while inflammation had 
an influence on the hypothalamic endocrine functioning, cor-
roborating the coexistence of depression in MS compared to 
other neurological disorders.25 The symptoms of depression 
are not closely related to disease severity and its progres-
sion, but they are more prevalent during the relapses and in 
increased neurological disability.20 Though much progress 
has been made in identifying the depressive pathological 
origins, their specificity still remains as a question. When 
observed in a group of RRMS patients with depression, the 
proinflammatory cytokine interferon (IFN)-γ was exces-
sively produced and was associated with symptom severity. 
However, when treated with antidepressive medication, 
the levels of IFN-γ were lowered, explaining its possible 
role in depressive pathology.26 Similarly, a case-controlled 
study observed exacerbations of depression in MS patients 
undergoing treatment with IFN-β.27 A few studies reported 
contradictory results revealing the uncertainty of MS med-
ication-induced depression.28–31 The major consideration of 
depression in MS is that it is associated with other behavioral 
disturbances such as disturbed cognition. Depression may 
aggravate cognitive dysfunction, which may induce depres-
sion, thus worsening the quality of life in all aspects.32
Observations by Alajbegovic et al33 revealed some 
interesting results. They found that depression was common 
among the MS population studied, with a majority of them 
being young, educated, unemployed, and single.33 A longi-
tudinal study also confirmed that the depression associated 
with MS is chronic and is usually episodic.34 Finally, the 
most interesting concept to understand is depression and its 
association with MS relapses. Though there are no substan-
tiating data to support this issue, it definitely seems to pose a 
fascinating question to be answered. In summary, depression 
stands as the major behavioral disorder observed in MS, with 
a potential of aggravating other behavioral abnormalities. 
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Hence, diagnosis and treatment of depression in MS will 
significantly improve the quality of life in patients.
Cognition and MS
Cognitive disturbances have been reported in 40%–60% of 
people with MS. Common manifestations include defects in 
recent memory and impaired attention, analyzing, visuospa-
tial perception, and executional activities.35 Impairment of 
cognition can be a potential indicator for the demyelination 
process36 and is more common and severe in the progressive 
form of the disease rather than the relapses.37 The results of 
the study conducted by Deloire et al38 also hypothesized the 
symptoms of cognitive impairment as a forerunner for MS 
disability, which follows several years later. The precise 
pathology of cognitive disturbances in MS has not been 
identified, but inflammatory lesions, regional degenera-
tion, and repetitive black holes somehow relate them to MS 
pathology.38
It has been previously reported that inflammatory cytok-
ines tend to cause cognitive disturbances, and the association 
of MS with inflammation indicates the role of cytokines in 
correlating MS pathology with that of cognitive impairment.39 
Loss of gray matter is quiet common among MS patients, and 
this also leads to the loss of cognitive function. Also, disrup-
tions of the cerebral cortex regions and the thalamus strongly 
associate memory impairment with that of MS pathology.
Causes of cognitive imbalance in MS
Old age, male sex, ApoE, the gene encoding for apolipopro-
tein E, and variations in brain-derived neurotrophic factor 
were evaluated as major risk factors associated with cognitive 
impairment among MS patients.40 Some studies reported dis-
ability of recognizing emotions in MS patients, which were 
elusive, and associated it with memory impairment,41 while 
some other studies correlated disability of emotion recogni-
tion and perception of behavioral aspects and quality of life.42 
Functional MRI studies have also proved that noticeable dif-
ferences exist between MS patients and controls in emotion 
recognition, highlighting the point of disturbed brain function 
and cognition.43–45 Other manifestations that tend to associate 
disturbed cognition with MS include fatigue and depression, 
which are more common in MS than in any other neurological 
diseases. These symptoms are correlated in MS, assuming 
that they share some commonness in pathology.46 Also, the 
levels of fatigue and depression were noticeably high in 
cognitively impaired MS patients and were evident from the 
measures of attention and memory, respectively.47 Clinically, 
an interesting question regarding the correlation between 
depression and cognition loss arises: would the treatment for 
depression in MS alleviate memory impairment?
Currently, no data are available, but in traumatic brain 
injury, patients have displayed improved cognition when 
treated for depression.48 Other factors that have a correla-
tion toward MS pathology and impaired cognition include 
dysregulation of the hypothalamopitutary–adrenal axis49 
and hypercortisolemia. Corticosteroids administered for MS 
treatment were found to worsen memory, particularly in the 
relapsing–remitting form of the disease.50
Biomarker measurement
Though modest in correlating cognitive impairment in MS 
with MRI markers, MRI has been invaluable in the diagnosis 
of cognitive impairment. The identified MRI markers are 
T2 and T1 lesional loads, with the former showing a limited 
correlation, while the latter better related brain atrophy 
with cognitive loss.20 Also, MS patients showed cholinergic 
imbalances; hence, measuring the levels of choline acetyl-
transferase and acetylcholinesterase will be ideal for manag-
ing cognitive impairment.51 In conclusion, cognitive loss is 
identified as an important symptom of MS that is found to 
significantly hamper daily activities, inclusive of social and 
emotional functionings. Though the exact pathology remains 
unclear, the inflammatory and degenerative processes 
observed in MS can be the major contributors of cognition 
impairment with a higher impact on executive functions.
Anxiety in MS
Though not much studied in MS patients, anxiety cannot be 
ignored as it can be an important contributor to disability 
in them. As per published data, many MS patients exhibit 
the symptoms of anxiety; in some cases, it is more frequent 
than depression.52,53
Comparatively, the symptoms of anxiety are more 
prevalent in MS patients than in controls, and risk factors 
include female sex, lack of caring, coexisting depression, 
and ignorance of anxiety symptoms.54 Animal studies have 
also found the association of inflammation, which is default 
in MS pathology, and anxiety underlying the probable 
occurrence of anxious symptoms in MS.21 Anxiety among 
MS patients needs strict medical attention as it was found 
to disrupt executive functioning. Intriguingly, cognition was 
severely affected than when compared to depression among 
the patient population studied.55 Depression and anxiety run 
together in a few MS patients and importance should be given 
to anxiety as it may enhance suicidal tendencies in these 
patients compared to patients exhibiting little or no anxiety.52 
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A cross-sectional study also observed symptoms of depression 
and anxiety occurring twice and thrice, respectively, among 
MS patients with no sex indifference for depression, while 
anxiety was reported more in males.56 Another interesting fea-
ture reported was that some patients presented the symptoms 
of anxiety well before the diagnosis of MS.57,58 Considering 
the predominance of anxious symptoms among MS patients, 
attempts had been made to identify the connection of exact 
brain regions involved in this pathology. But still it has not 
been fruitful as correlation between anxious symptoms and 
brain MRI scans lacked correlation.24 The impact of anxiety 
in different forms of the disease was studied and contradic-
tory results were observed. Some studies had reported that 
relapses in RRMS were more often associated with anxiety 
and disclosed higher levels of anxious symptoms,59 whereas 
studies by Noy et al53 and Brown et al60 reported the associa-
tion of anxiety and relapses to be rather conflicting.
The advent of self-administered immunomodulatory 
drugs for MS has led to the induction of anxiety named 
“self-injection anxiety” and was reported to affect almost 
half of the MS population following this practice.61 Clinical 
studies have also revealed an increased prevalence of anxiety 
among the MS patients adding an interesting finding towards 
the MS associated behavioural compromise. Patients who 
were included in the study did not show severe neurologi-
cal compromise but were certainly distressed as they were 
unable to cope up with the disease and get relief. Other 
reasons for developing anxiety were anticipated to be strong 
fear of developing personal and professional lagging, as the 
patients were emotionally preoccupied and compromised for 
a complete cure.62 In summary, it is quiet natural that people 
are concerned with health and become anxious, particularly, 
if affected with a chronic disease or a disease with no cure at 
all. Thus, MS, being a chronic disorder with incomplete cure, 
poses the symptoms of anxiety. The question to be answered 
in this scenario is to identify the pathologies that are common 
to MS and anxiety and to target them specifically.
Psychosis and its association with MS
Psychosis and MS share a common pathophysiology and the 
symptoms are displayed due to regional demyelination during 
the disease progression. The association was also exacerbated 
due to the medications for MS. IFN-β administered to lower 
autoimmunity in MS produced psychotic symptoms, while 
a reduction in these symptoms was noticed on administra-
tion of antipsychotic medication.63 Brain MRI has also not 
shown any significant changes pre- and post-IFN treatment, 
strengthening the fact of medication-induced psychosis.64
In a group of comparative studies among MS patients 
with psychosis and those devoid of psychosis, lesions were 
found to be more prominent in the MS psychotic patients 
than in those without psychosis.65,66 These lesions were 
more specific to the periventricular white matter of the 
temporal horn regions, and many studies have also associ-
ated psychotic symptoms in MS with lesions, substantiating 
the role of regional demyelination in the pathology of MS 
psychosis.67,68 There are also studies focusing on the involve-
ment of other brain regions such as temporal, frontotemporal, 
and temporoparietal lesions, associating psychic symptoms 
in MS patients69,70 with temporal and frontotemporal and 
temporoparietal abnormalities.71 There is a growing inter-
est to explore the exact relation between psychosis and MS 
pathology, as several large-scale studies have also pointed 
out the coexistence of them. It poses a serious challenge in 
terms of both treatment and diagnosis when these patholo-
gies run together.72,73 Clinicians have also highlighted the 
point that psychic patients who do not respond to standard 
antipsychotic regimen should be diagnosed for the underly-
ing MS pathology. Hence, preferably, MS needs differential 
diagnosis both for effective therapeutic outcome and ruling 
out psychotic symptoms.74,75
euphoria
Euphoria affects approximately 10% of the MS population 
and is best described as the phase of cheerfulness without 
displaying the symptoms of motor hyperactivity. It is related 
to the frontal lobe pathology, which is common in several 
other personality disorders, along with the involvement of 
brainstem, pontine, and periventricular lesions. Interesting 
correlation was drawn from a study where the association of 
euphoric symptoms in MS was related to severe cognitive 
disturbances rather than to disease exacerbations, indicating 
extensive brain pathology.
This study also concluded that euphoric symptoms are 
predisposed regardless of the sex and are mostly associated 
with the progressive form of MS and its severity.76
Sleep and fatigue
As MS is associated with behavioral symptoms, it strongly 
influences sleep patterns and the associated disturbances. 
Sleep disturbances in MS patients were related to the degen-
erated regions involving the basal ganglia, thalamus, and 
limbic system.77 It has been reported that a majority of the 
MS patients display symptoms of insomnia, narcolepsy, sleep-
related breathing abnormalities, and rapid eye movement sleep 
behavior disorder, thus significantly influencing quality of 
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life.78,79 Clinical studies also revealed sleep disturbances in 
terms of onset and duration of sleep among MS patients.80
Fatigue in MS
The other major manifestation of MS is the perception 
of fatigue, and multiple factors are involved in its origin, 
which include elevated body temperature and cytokine lev-
els, hyperactive hypothalamic–pituitary–adrenal axis, and 
some medications for associated disorders like depression 
and spasticity.78,81,82 Though fatigue is quiet common among 
MS patients, it is incompletely understood. However, two 
subtypes of fatigue have been reported. These are motor 
fatigue, which develops due to excess muscular stress, and 
mental fatigue, which develops due to the intense level of 
tiresomeness. The etiology of fatigue overlaps with that of 
other associated disorders and hence can be considered as 
both primary fatigue, which is purely associated with MS, 
and secondary fatigue, which is related to the comorbidity.
The symptoms of fatigue mainly arise due to neuronal 
demyelination, which severely hampers neurotransmission. 
In the recent past, fatigue in MS had been related to pari-
etotemporal and frontal region lesions.83 Neurotransmitter 
imbalances, excessive muscular stress, lesions in other brain 
regions, coexisting disturbances, and medications for MS are 
other possibilities of fatigue generation.84
Sleep–fatigue correlation
Interesting correlations also exist between symptoms of sleep 
disturbances and fatigue in MS patients. A comparative study 
of healthy controls and MS patients concluded that sleep 
abnormalities were common among MS patients and showed 
a strong correlation with fatigue. However, this correlation 
was not observed in the healthy controls.85 Altogether, a pre-
cise relationship has not been established between sleep and 
fatigue; the published data suggest an interrelation between 
them. Thus, sleep disturbances and fatigue either indepen-
dently or collectively influence the quality of life in MS 
patients. The association of pathology of all the behavioral 
disorders with that of MS is shown in Table 1.
Behavioral screening studies for MS
Although several animal models exist for studying behavioral 
changes in MS, the experimental autoimmune encephalomy-
elitis (EAE) induced by myelin oligodendrocyte glycoprotein 
is the most widely accepted mouse model that mimics MS 
in humans.86 As MS is associated with several behavioral 
abnormalities, animal models serve as extremely useful tools 
for assessing and developing novel therapeutic approaches. For 
example, analyzing the locomotor activities in these animal 
models provide useful information on the involvement of spe-
cific pathologies. A brief introduction of them is as follows:
Open field test
This test screens for spontaneous locomotor activity. In 
this test, animals are allowed to move and explore freely 
in an enclosed square area while being monitored for their 
locomotor activity.21
Grid walk test
This test provides valuable information on the formation of 
lesions in the dorsal column and descending motor control 
abnormalities by analyzing an animal’s ability to place its 
Table 1 Association of MS with behavioral disorders
Serial  
number
Behavioral 
disorder
Pathology of MS  
involved
Regions involved Significance References
1 Depression Inflammation, pleocytosis Arcuate fasciculus, frontotemporal 
region
Major behavioral disorder Harel et al19 
McDonald and 
Ron20
2 Cognition Inflammatory lesions, regional 
degeneration, gray matter 
loss, repetitive black holes
Cerebral cortex regions and 
thalamus
Forerunner of 
demyelination
Feinstein32
3 Anxiety Inflammation – Symptoms are a predispose 
for MS diagnosis
Feinstein et al52
4 Psychosis Regional demyelination Periventricular white matter of the 
temporal horn region
Lesions more predominant 
in MS psychotic patients
Feinstein et al64 
Honer et al66
5 euphoria Inflammatory lesions Frontal lobe extensive brain pathology Kosmidis et al76
6 Sleep Neuronal loss Basal ganglia, thalamus, limbic 
system
Sleep abnormalities and 
fatigue strongly correlate 
with each other
Kanyak et al80 
Tachibana et al82
7 Fatigue Lesions Parietotemporal and frontal regions
Abbreviations: MS, multiple sclerosis; -, not reported.
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hindlimbs on bars. Animals are trained to walk on a runway 
consisting of bars placed at an elevation of 1 m above the 
ground. Comparatively, the number of falls were higher in 
the MS-induced animals than in the controls when they tried 
placing their hindlimbs firmly on the bars.87 Other tests for 
assessing locomotor activities include BBB open field loco-
motion score and narrow beam test.88
Rota rod analysis
This is the highly accepted test for assessing forced motor 
moments in rodents. Initially, animals are trained on a rotat-
ing rod at a speed of 4–40 rotations per minute and then the 
grip strength is analyzed by observing the animals’ latency 
fall from the rotating rod.86
Learned helplessness paradigm
This test mainly aims at studying the depressive episodes 
in animal models conducted in a customized shuttle box 
equipped with a shock generator and the software for con-
trolling, processing, and recording. Initially, the animal is 
conditioned with a phase of inescapable foot shocks and 
then placed in a testing chamber, from where it can escape 
to a shock-free chamber.
After sufficient training, the animal is subjected to the 
same escapable foot shocks, but this time, a light stimulus 
strikes before the shock is applied. The ability of the animal 
to avoid the shock with each light stimulus and to escape into 
the shock-free chamber is tested. If the animal fails to do so, 
it is assumed as learned helplessness behavior.89
Light/dark box
The light/dark box model measures anxiousness. In this 
model, animals (mice) are placed in a light and dark com-
partment, and exploratory behavior is monitored. The 
analysis is done based on the length of time spent by the 
animals and number of crossings they make into the lighted 
compartment, assuming these activities to be reflective of 
anxious behavior.21 A summary of behavioral screening in 
MS is shown in Figure 2.
MS therapeutics and applications 
of nanotechnology
The strategic treatment for MS is mainly concerned to alleviate 
its symptoms and associated disease progression. The first-line 
drugs considered for the treatment of MS are IFNs, particu-
larly type 1 and include IFN-β1a and IFN-β1b, along with 
glatiramer acetate. Their mechanism is mainly targeted against 
the reactive T-cell activity with a strong inhibition of T-cell 
proliferation, migration, and antigen presentation.90 Interesting 
outcomes were seen when the first-line drugs were combined 
with a natural metabolite, methyl thioadenosine, that possessed 
potent immunomodulatory activity preclinically.91 Corticoster-
oids with a mechanistic activity of immune suppression were 
also effective against MS and its progression. Dexamethasone, 
prednisone, prednisolone, and methylprednisolone are some of 
the corticosteroids used to treat MS. However, indiscriminate 
and long-term use of these drugs is strictly discouraged on 
account of their severe side effects.92
Chemotherapeutics like cyclophosphamide and mitox-
antrone with a background history of immune suppression 
were found to be efficacious in treating MS. With respect to 
the mechanism of action, cyclophosphamide showed activity 
against T and B lymphocytes, while mitoxantrone was found 
to be cytotoxic.93,94
Monoclonal antibodies
Monoclonal antibodies (mAbs) have made significant contri-
butions toward MS therapeutics. For instance, natalizumab, 
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Figure 2 MS and its associated behavioral tests.
Notes: MS is associated with several behavioral abnormalities, and the studies of these disorders involve the development of animal models mimicking them. These behavioral 
tests can serve as useful tools for evaluating and developing effective therapeutics against common behavioral disorders in MS.
Abbreviation: MS, multiple sclerosis.
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a humanized mAb, when tried in a patient population resulted 
in significant reduction in disease recurrence with an action 
against α-integrins (cell surface molecules essential for 
T-cell binding and entry). However, long-term use poses 
the risk of progressive multifocal leukoencephalopathy. 
mAbs under evaluation include alemtuzumab (Campath) and 
rituximab, which were observed to have a potential activity 
against the expression of CD52 and CD20 on leucocytes. 
When administered to a patient population, they resulted in 
a considerable reduction in the levels of inflammatory mono-
cytes, lymphocytes, and dendritic cells.95,96 Daclizumab is a 
humanized mAb that acts against CD25 expression, thereby 
limiting the proliferation of reactive T-cell. This drug has 
recently finished its Phase II trial.97
Drug trials
The drug in trials with a prime motto of ameliorating disease 
progression and severity is the oral formulation BG00012. Its 
active principle is fumarate. It has the characteristic mecha-
nisms of neuroprotection, relieving inflammatory cascade 
and oxidative stress.
Fingolimod is one of the class of MS therapeutics with 
an activity of lymphocyte complexatoin. BG00012 is in 
Phase II clinical trials,98 and fingolimod has recently received 
approval for human use.99 Firategrast, an antagonist for the 
very late antigen-4 (a cell adhesion molecule expressed on 
brain capillary cells) has finished its Phase II clinical trial 
and acts by inhibiting the entry of T-lymphocytes into the 
BBB. Laquinimod and teriflunomide are the representatives 
for drugs in Phase III trials, and their mechanisms include 
the immune response shift toward Th2 type and inhibition 
of lymphocytic expansion.16,100 A proprietary recombinant 
human IFN-β1b (NU 100) and an extended-release poly-
ethylene glycol coated IFN-β1a (BII-B017) are in Phase III 
trials for the treatment of RRMS.101
Applications of nanotechnology
Nanotechnology has always been fascinating as it deals with 
ultrasmall particles with a dimension range of 1–100 nm. Spe-
cific advantages attributed to these nanoparticles (NPs) consid-
ering their size and durability are that they offer huge surface 
area, improving bioavailability and absorption, and enhanced 
physicochemical stability of theranostics (therapeutic + diag-
nostics). A unique feature of this technology is that NPs can 
be tailor-made for specific targets, thus nullifying unwanted 
biodistribution and achieving the maximum efficacy at a 
reduced drug dose.91 The same application would also benefit 
drug permeation through the complex BBB, which is viewed 
as a major hurdle for conventional drugs to pass through. 
When applied, this technology would certainly benefit the 
nervous system, promoting the viability and integrity of 
neurons that have a limited regenerative capacity. Hence, 
nanotechnology holds a strong future potential for theranostic 
applications against a variety of neurological disorders and 
thus overcome the limitations of existing therapeutics. The 
following is a brief description of NP application in MS. It 
is evident that matrix metallopeptidase-9 (MMP-9) plays a 
pivotal role in disrupting the BBB, thereby attracting periph-
eral T-cells and thus initiating the neuroinflammation cascade. 
A study has shown that the quantum dot complexed with 
MMP-9–small interfering RNA (nanoplex) has significantly 
blocked the expression of MMP-9 in brain microvascular 
endothelial cells and leukocytes. In addition, upregulation 
of extracellular matrix proteins like collagen types I, IV, and 
V was observed, indicating the successful delivery and effi-
cacy of small interfering RNA nanoplex in vitro.102 Tissue 
inhibitor of matrix metalloproteinase-1 is a potent inhibitor 
of MMP-9, which is one of the main culprits associated with 
neuroinflammation. A study reported encapsulation of tissue 
inhibitor of matrix metalloproteinase-1 in poly(lactic-co-gly-
colic) acid NPs and strong neuroprotective activity in vitro by 
inhibiting the gelatinase-mediated MMP-9 activity.103 Inter-
esting results were reported showing the antioxidant activity 
of fullerene (C60), where C60 suspension on administration 
showed strong protective activity against carbon tetrachloride 
intoxication in rats.104 This could be a potential application if 
tested against disorders such as MS that are associated with 
free radical toxicity. In an EAE model induced by the proteo-
lipid protein PLP
139–151
 administration, significant improved 
tolerance was observed in mice that were administered in prior 
with the PLP
139–151
-coupled poly(lactic-co-glycolic) acid NPs. 
Antigen-presenting cells internalized these NPs via scavenger 
receptors and induced both T-cell anergy and enhanced T-reg 
activity. The disease improvement was also confirmed with 
the vascular (AngioSense 750EX) and protease-activatable 
cathepsin B (Cat B 680 FAST) near-infrared fluorescence 
imaging agents, which showed a respective decrease in the 
BBB breakdown and inflammation.105
The T-cell regulatory activity was also improved in 
an autoimmune model, wherein the authors fabricated 
disease-relevant self-peptides and the class I peptide–major 
histocompatibility complex-coated iron oxide NPs.106 Thus, 
the antigen-specific T-reg cell expansion can be a potential 
approach if modified using the MS specific antigen. Similar 
results were also reported where gold NPs carrying 2-(1′H-
indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester 
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and myelin oligodendrocyte glycoprotein showed significant 
disease remission. NP-treated dendritic cells showed a tole-
rogenic phenotype and induced the differentiation of T-reg 
cells, which significantly abrogated disease generation.107 
The monolayer mannosylated liposomes packed with vari-
ous immunodominant myelin basic protein (MBP) fragments 
showed significant reduction in the level of anti-MBP anti-
bodies. This nanoformulation showed a synergetic therapeu-
tic effect, wherein disease scores were reduced showing a 
first EAE wave inhibition followed by subsequent remission 
in vivo.108 Gold NPs encapsulated with potential antioxidant 
compounds epigallocatechin gallate, and α-lipoic acid were 
found to have strong wound healing and migration along with 
an increase in the antioxidant activity in vivo. This could be 
a future application for evaluating against MS pathology.109 
Cerium oxide (CeO) NPs are regarded as potent antioxi-
dants on account of their ability to either donate or receive 
electrons. It was also reported that CeO NPs showed an 
extremely small size of 2.9 nm with enhanced brain uptake 
and reduced reactive oxygen species in vivo. The authors 
claim that custom-made CeO NPs provide protection against 
autoimmune diseases associated with free radical toxicity.110 
Further to this, a novel pH-sensitive IFN-β microparticle was 
synthesized using trimethyl-chitosan, poly(ethylene glycol)-
d-methacrylate, and methacrylic acid. These microparticles 
showed effective drug release over 24 hours both in vitro 
and in vivo.111
Neuroprotection was also made possible with the implica-
tion of fullerenol (polyhydroxylated C60), which mitigated 
neuronal excitotoxicity antagonizing the glutamate recep-
tors in amyotrophic lateral sclerosis model.112 This function 
of fullerenol also holds potential application for MS too. 
The implication of nanosurgery is underway and is at the 
threshold of revolutionizing neurological disorders. Earlier, 
nanosurgery was only a dream, but now the current nano tools 
have made the dream come true. The introduction of quantum 
dots for imaging, multipartite NPs for neuromodulations, and 
nano manipulations mediated by atomic force microscopy 
cantilever have all made it possible.113 A study reported the 
use of atomic force microscopy tip as nanoscissors for indent-
ing the cell wall by only 1 µm, which otherwise is inevitably 
difficult employing conventional techniques.114 This kind of 
applications opens up new avenues for single-cell and chro-
mosomal surgeries operating at submicron levels and would 
highly benefit the MS brain where damaged neurons can be 
successfully treated without affecting the healthy ones. NPs 
not only have a role in therapeutic application, but have also 
improvised the diagnostic strategy with enhanced sensitivity, 
enabling early detection of the disease. Likewise, the titanium 
dioxide nanocomposite film modified with alginate coat has 
been immobilized with MBP, and when tested for antigen 
detection, it showed an astounding sensitivity of 0.18 ng/mL. 
Thus, NPs have improved MS diagnosis, wherein a blood 
sample is sufficient instead of CSF samples.115 MS diagno-
sis was even improved with the application of very small 
superparamagnetic iron oxide particles, which showed a 
characteristic accumulation in the inflammatory lesions. The 
very small superparamagnetic iron oxide particles were also 
successful in discriminating inflammatory events between 
control and established EAE, with clear demarcation of the 
central nervous system alterations preceding immune cell 
infiltration.116
Similarly, detection sensitivity was enhanced using the 
streptavidin antibody-conjugated superparamagnetic iron 
oxide particles, as they are superior contrast agents because 
of their T
2
* relaxation properties. These target-specific NPs 
were able to visualize CD3+ T-cell infiltrates in a murine 
MS model, confirming the diagnostic potential of NPs.117 
Some recent advancements were made with the introduc-
tion of gadolinium–diethylene triamine pentaacetic acid 
and ultrasmall superparamagnetic particles of iron oxide 
(USPIO). Gadolinium–diethylene triamine pentaacetic acid is 
a routinely employed inflammatory marker,118 while USPIO 
can detect cellular infiltration and inflammation progression 
in MS.119 The application of stem cell therapeutics has also 
garnered significant attention; it was found that patients 
administered with autologous hematopoietic stem cells 
showed much improved outcome in Phase II trials.120,121 
Further, coupling nanotechnology platforms would impro-
vise the stem cell-based theranostics. For instance, carbon 
nanotube substrates regulate growth and neurite regeneration, 
which can find potential application for neural regenera-
tion.122 Intriguingly, USPIOs can label stem cells and help 
in tracking the fate of these cells using MRI.123 Table 2 sum-
marizes the list of nanotechnology applications in MS.
what is in the pipeline?
Agents possessing neuroprotective activity are worth consid-
ering as treatment for MS, and histone deacetylase inhibitors 
is one such class possessing strong anti-immune activity.124 
Inflammatory insults play a major role in the onset and pro-
gression of MS, and hence therapeutics acting against it can 
be invaluable. Likewise, inhibitors of midkine (a cytokine 
that drives T-cell traffic followed by inflammatory cascade) 
are under development, as they have shown a remission 
preclinically in an MS model.125
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Table 2 various nanotechnology applications in MS
Serial 
number
Nano 
application
Composition Remarks References
1 Therapeutic Quantum dot complexed with the 
MMP-9–siRNA (nanoplex)
Reduced MMP-9 expression in brain 
microvascular endothelial cells and leukocytes
Bonoiu et al102
2 Tissue inhibitor of MMP-1-loaded PLGA NPs Inhibition of MMP-9 and inflammation Chaturvedi et al103
3 PLP139–151-coupled PLGA NPs Disease abrogation via T-cell anergy and 
enhanced T-reg activity
eaton et al105
4 pMHC-coated iron oxide NPs Disease abrogation via T-reg cell expansion Tsai et al106
5 iTe- and MOG-loaded gold NPs Dendritic cell-induced T-reg cell differentiation Yeste et al107
6 Mannosylated liposomes carrying MBP 
fragments
Nullified MBP antibodies showing EAE abrogation Stepanov et al108
7 epigallocatechin gallate- and α-lipoic acid-
loaded gold NPs
Strong antioxidant activity Leu et al109
8 CeO NPs Strong antioxidant activity Heckman et al110
9 Fullerene (C60) suspension Strong antioxidant activity Gharbi et al104
10 Nano-encapsulated H. pylori Hypothesized for future MS therapy Pezeshki et al130
11 Trimethyl chitosan-loaded iFN-β 
microparticles
Sustained drug release Kondiah et al111
12 Fullerenol (polyhydroxylated C60) Strong neuroprotection antagonizing glutamate 
receptors
Dugan et al112
1 Surgery Quantum dots Best for imaging Jeffries et al113
2 Multipartite NPs Best suited for neuromodulations
3 Atomic force microscopy Suitable for submicron level operations involving 
single-cell and chromosomal surgeries
Obataya et al114
1 Diagnosis MBP-coated TiO2 nanocomposite films enhanced detection sensitivity of 0.18 ng/mL Derkus et al
115
vSOP NPs Specific accumulation and detection of 
inflammatory lesions
Millward et al116
2 Streptavidinated CD3+ antibody-conjugated 
SPiO NPs
visualization of CD3+ T-cell infiltrations Luchetti et al117
3 Gadolinium–DTPA Routinely employed inflammatory marker Heta et al118
4 USPiO Detects cellular infiltration and inflammation 
progression
Richards et al119
Abbreviations: CeO, cerium oxide; DTPA, diethylene triamine pentaacetic acid; eAe, encephalomy elitis; H. pylori, Helicobacter pylori; iFN, interferon; iTe, 2-(1′H-indole-3′-
carbonyl)-thiazole-4-carboxylic acid methyl ester; MBP, myelin basic protein; MMP, matrix metalloproteinase; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; 
NPs, nanoparticles; PLGA, poly(lactic-co-glycolic) acid; PLP, proteolipid protein; pMHC, class i peptide–major histocompatibility complex; siRNA, small interfering RNA; SPiO, 
superparamagnetic iron oxide; TiO2, titanium dioxide; USPiO, ultrasmall superparamagnetic particles of iron oxide; vSOP, very small superparamagnetic iron oxide particles.
Physiologically, carbon monoxide has some anti- 
inflammatory and cytoprotective activities. Interestingly, 
when carbon monoxide-releasing molecules were tested 
preclinically in the EAE model, they were found to alleviate 
the pathologic disease scores, driving the need for clinical 
evaluation.126 The potential immunomodulatory role of vita-
min D is also being evaluated in a Phase II trial.127 Table 3 
gives a summary of the drugs included.
Future trends
As per the data published, there is commonness in the 
pathologies of MS and some behavioral disorders. Hence, 
selectively identifying and targeting the events of MS will 
also prove to be potential for the alleviation of comorbidi-
ties. Some of our own results are discussed here. We have 
adopted the principle of neuroprotection and observed 
anti-inflammatory effects of anti-mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1) mAb, which protected 
oligodendrocytes. Also, simultaneous administration of 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate/kainate 
antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)qui-
noxaline and the neuroprotector glycine–proline–glutamic 
acid (N-terminal tripeptide of insulin-like growth factor) 
resulted in strong neuroprotector activity, confirmed with the 
significant reduction in impaired neurological scores in vivo.4 
More rapid disease remittance was observed in mice when 
a combination of anti-MAdCAM-1, vascular cell adhesion 
molecule-1, intercellular cell adhesion molecule-1, and ligand 
for lymphocyte function-associated antigen integrin mAbs 
was administered.128 Also, the contribution of integrin (α4β7 
and αEβ7)-mediated inflammation in MS was significantly 
remitted, administering antibodies against them.129
Thus, after the analysis of the results, we assume that 
the antibodies targeting the inflammatory ligands involved 
in MS may also impede the inflammatory component of the 
depressive episodes and cognitive impairment followed by 
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Table 3 Current drugs in trials for MS treatment
Serial 
number
Drug Mechanism of action Level of study References
1 iFN-β1a, iFN-β1b, and glatiramer 
acetate
inhibition of T-cell proliferation, 
migration, and antigen presentation
Completed Chourbaji et al90
2 Corticosteroids immune suppression Completed Moreno et al92
3 Cyclophosphamide and mitoxantrone immune suppression Completed Chan et al93 
Fauci et al94
4 Methyl thioadenosine immunomodulatory activity Preclinical Moreno et al92
5 Natalizumab inhibition of T-cell migration Phase iii Buck and Hemmer95
6 Alemtuzumab Anti-CD52 and depletion of lymphocytes Phase iii Buck and Hemmer95
7 Rituximab Anti-CD20 and depletion of 
B-lymphocytes
Phase iii Buck and Hemmer95
8 Daclizumab Anti-CD25 and depletion of reactive 
T-lymphocytes
Phase ii completed Hauser et al97
9 BG00012 Inhibition of inflammation and oxidative 
stress
Phase ii Saidha et al98
10 Fingolimod inhibition of T-cell entry into the brain FDA approved Lutterotti99
11 Firategrast Phase ii completed Buck and Hemmer95
12 Laquinimod immune response shift toward Th2 type Phase iii Yang et al100
13 Teriflunomide inhibition of the lymphocytic expansion warnke et al131
14 Histone deacetylase inhibitors Anti-inflammatory and neuroprotective Preclinical Faraco et al124
15 Midkine inhibitors Muramatsu125
16 Carbon monoxide-releasing molecules Fagone et al126
17 vitamin D immunomodulatory actions Phase ii Dorr et al127
Abbreviations: FDA, US Food and Drug Administration; iFN, interferon; MS, multiple sclerosis.
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Figure 3 Strategic treatment for MS.
Notes: (A) Permeation inhibitors bind either with cell adhesion molecules present on the capillary endothelium or cell surface molecules of the reactive T-cells and prevent 
them from gaining access into the brain (eg, iFN-β1a, natalizumab). (B) mAbs particularly target the T- and B-cells based on their surface markers and eventually deplete 
them (eg, daclizumab and rituximab target CD25 and CD20 expressed on T- and B-cells, respectively, and deplete them). (C) immunomodulators such as corticosteroids, 
chemotherapeutics, and the lead compound laquinimod act against immunity by suppressing it or shift the immune response to Th2 type. (D) Neuroprotectors such as 
BG00012 and histone deacetylase inhibitors (under evaluation) and protect neurons from the insults of inflammation and free radical stress.
Abbreviations: iFN, interferon; mAbs, monoclonal antibodies; MS, multiple sclerosis; BBB, blood–brain barrier.
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their remission. Hence, it is postulated that identifying and 
targeting the pathological events specific to MS can definitely 
prove to be beneficial for relieving the comorbid behavioral 
symptoms as well. This is because of the findings of com-
monness in the pathologies of MS and behavioral disorders. 
Future also holds an interesting question to answer: shall the 
treatments initiated for behavioral symptoms improve MS 
too? Figure 3 shows strategic treatment options for MS.
Conclusion
Behavioral disturbances are found to be common among MS 
patients, irrespective of the severity and the course of dis-
ease progression. Depression seems to be the most common 
neuropsychiatric abnormality observed in MS compared to 
any other neurological disorders. It is also associated with 
cognitive impairment in few of the MS patients, raising the 
question of commonness in their pathology. It is worthwhile 
to identify the early symptoms of this memory loss, as it is 
considered to be a forerunner of MS in a group of patients. 
Psychosis, euphoric symptoms, sleep disturbances, and 
fatigue are other influential comorbidities associated with 
MS that will drastically affect the quality of a patient’s life. 
Hence, identifying disease-specific targets and coupling them 
with NPs will result in the effective diagnosis and treatment 
of the disease. This would also positively affect and help 
overcome the associated behavioral symptoms in MS. “The 
better the quality of life, the better the recovery”.
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